Stem cell-derived gametes: what to expect when expecting their clinical introduction

  • Ilse J. de Bruin
  • , Merel M. Spaander
  • , Simone Harmsen
  • , Rosanne Edelenbosch
  • , M. Corrette Ploem
  • , Nina Dartee
  • , Madalena Cardoso Vaz Santos
  • , Mathangi Lakshmipathi
  • , Callista L. Mulder
  • , Ans M. M. van Pelt
  • , Willy M. Baarends
  • , Susana M. Chuva de Sousa Lopes
  • , Guido M. W. R. de Wert
  • , Seppe Segers
  • , Geert Hamer*
  • , Ana M. Pereira Daoud*
  • , HipGametes Consortium
  • *Corresponding author for this work

Research output: Contribution to journal(Systematic) Review articlepeer-review

Abstract

Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.
Original languageEnglish
Pages (from-to)1605-1615
Number of pages11
JournalHuman Reproduction
Volume40
Issue number9
Early online date1 Jul 2025
DOIs
Publication statusPublished - 1 Sept 2025

Keywords

  • stem cell-derived gametes
  • in vitro gametogenesis
  • human
  • induced pluripotent stem cells
  • clinical application
  • assisted reproductive technologies
  • ethics
  • law
  • society
  • IN-VITRO GAMETOGENESIS
  • ESHRE TASK-FORCE
  • FETAL TISSUE
  • FOLLOW-UP
  • ETHICS
  • RECONSTITUTION
  • DONATION
  • PERSPECTIVES
  • DISCLOSURE
  • INDUCTION

Fingerprint

Dive into the research topics of 'Stem cell-derived gametes: what to expect when expecting their clinical introduction'. Together they form a unique fingerprint.

Cite this